

DBB

MOLECULAR PHARMACOLOGY

AN INTERNATIONAL JOURNAL

VOLUME 38
NUMBER 2
AUGUST 1990

FOUNDED BY AVRAM GOLDSTEIN - 1965

ASPET

A PUBLICATION OF THE AMERICAN SOCIETY FOR
PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS



Published by Williams & Wilkins

Broad coverage of pharmacology
in a prestigious journal

THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS


Editor: **Eva King Killam, PhD**, School of Medicine, University of California, Davis

JPET is respected the world over as one of the leading research journals in the field of pharmacology. Readers find broad coverage of all aspects of the interactions of chemicals with biological systems, including:

- autonomic pharmacology
- analgesia
- behavioral pharmacology
- cardiovascular pharmacology
- cellular pharmacology
- chemotherapy
- clinical pharmacology
- developmental pharmacology
- drug abuse
- drug metabolism & disposition
- gastrointestinal pharmacology
- immunopharmacology
- neuropharmacology
- pulmonary pharmacology
- renal pharmacology
- toxicology

JPET is valuable reading for academic, industrial and clinical pharmacologists as well as toxicologists. The Journal deserves a place in every pharmaceutical and toxicological research laboratory and pharmacology/toxicology department throughout the world.

Monthly



YES! Enter my subscription:

Avoid future rate increases and ensure uninterrupted service - enter your multiyear subscription today!

The Journal of Pharmacology and Experimental Therapeutics
(monthly)

Individual: \$160/yr Institutions: \$260/yr

(Please add \$55 outside the U.S.)

New Subscription Renewal 3 yrs 2 yrs 1 yr

name _____

address _____

city/state/zip _____

Payment options:

Check enclosed Bill me MasterCard American Express

card # _____

signature P.O. # _____

MD residents, please add 5% sales tax. Subscriptions from outside the U.S. and Canada must be prepaid, in US dollars only. Rates valid for orders received before October 31, 1990.

Please allow 10 weeks for delivery of your first issue. Surface mail delivery to countries outside the U.S. may take up to 16 weeks. Airmail rates available upon request.

Williams & Wilkins

PT 52004

P.O. Box 23291
Baltimore, Maryland 21203 9990

Broadway House
2-6 Fulham Broadway
London SW6 1AA England

J0020S01



STABLE EXPRESSION OF HUMAN DRUG METABOLISM IN CELL CULTURE

GENTEST Corporation announces the development of immortal human lymphoblastoid cell lines which stably express human cytochrome P450s. These cell lines provide a reproducible source of human cytochrome P450s. The cells lines and microsomal preparations from the cell lines are available for toxicology and pharmacology research applications. This system:

- Provides a convenient means to analyze human metabolites.
- Provides an unlimited source of reproducible material.
- Avoids the large variability among human tissue samples.
- Allows analysis of cytochrome P450 form specificity without laborious purifications of enzymes or antibodies.
- Provides a means to analyze for clinically significant drug metabolism polymorphism early in drug development.
- Allows measurement of cytotoxicity and the induction of genetic damage in cells expressing the cytochrome P450.

The following human cytochrome P450s have been stably expressed by GENTEST in cell culture:

P450IA1	Aryl Hydrocarbon Hydroxylase
P450IA2	Phenacetin O-Deethylase
P450IIA3	Coumarin Hydroxylase
P450IID6	Debrisoquine Hydroxylase
P450IIIA4	Nifedipine Oxidase

Cell lines expressing additional human cytochrome P450s are under development.

For further information contact:

GENTEST Corporation
6 Henshaw Street
Woburn, MA 01801 USA
Tel: (617) 935-5115
FAX: (617) 938-8644